Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07544160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.
Trial Details
NCT Number NCT07544160
Lead Sponsor iCell Gene Therapeutics
Collaborators: iCAR Bio Therapeutics Ltd.
Conditions
(from sponsor)		 Inflammatory Bowel Diseases (IBD)
Related terms Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov